|Bid||4,680.00 x 6100|
|Ask||4,800.00 x 13000|
|Day's Range||4,710.50 - 4,791.00|
|52 Week Range||4,260.00 - 5,520.00|
|PE Ratio (TTM)||20.05|
|Earnings Date||May 18, 2018|
|Forward Dividend & Yield||2.53 (4.37%)|
|1y Target Est||74.66|
Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
If you avoided getting a flu vaccine this year because you're needle-phobic, there's good news: the nasal spray is coming back. The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices voted 12 to 2 Wednesday to allow FluMist, the only non-injected flu vaccine approved for use in the United States, to return to the disease prevention arsenal for the 2018-2019 flu season after a two-year suspension.
A key federal committee gave its OK for pediatricians to make MedImmune's FluMist available to patients in the next flu season — a big win for parent company AstraZeneca which saw its flu vaccine's U.S. sales decimated in the last two flu seasons because of previous negative recommendations. The positive, albeit cautious, recommendation came Wednesday from a Centers for Disease Control and Prevention advisory committee on immunization practices. It followed MedImmune's presentation of new research around FluMist, the intranasal spray vaccine manufactured by the Gaithersburg research and development arm of London parent AstraZeneca PLC (AZN).
The latest recommendation follows results from a U.S. study in young children that showed vaccines containing a 2017-2018 strain of H1N1 flu virus performed better than the 2015-2016 strain that had shown decreased effectiveness, AstraZeneca said.
AstraZeneca Plc said on Wednesday an advisory committee of the U.S. Centers for Disease Control and Prevention recommended the use of its FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position. The latest recommendation follows results from a U.S. study in young children that showed vaccines containing a 2017-2018 strain of H1N1 flu virus performed better than the 2015-2016 strain that had shown decreased effectiveness, AstraZeneca said.
Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity. Novo Nordisk, the world's biggest insulin maker, launched Ozempic, known generically as semaglutide, in the United States this year after it was approved by the U.S. Food and Drug Administration in December. Ozempic is a once-weekly injection that Novo Nordisk hopes will take market share from Trulicity, which has been cutting into sales of Novo Nordisk's once-daily Victoza.
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.
NEW YORK, NY / ACCESSWIRE / February 20, 2018 / U.S. markets closed Friday with weekly gains in the range of 4 percent to 5 percent. The Dow Jones Industrial Average gained 0.08 percent to close at 25,219.38, ...
Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.
AstraZeneca’s R&D-led turnround strategy received an important boost on Monday after US authorities approved the use of one of its key new lung cancer drugs, reinforcing the medicine’s potential to become ...
AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. The U.S. Food and Drug Administration (FDA) said late on Friday it had granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body. Imfinzi is the first immunotherapy to be approved in this setting and the company's shares rose 1 percent in early trade on Monday.
AstraZeneca’s turnround efforts received a boost on Monday as US authorities approved the use of one of its key new lung cancer drugs. The Food and Drug Administration has approved Imfinzi for treating ...
The Pacific is the biggest, deepest and least explored place on Earth. The implications of AstraZeneca ’s namesake drug trial also take some fathoming. News that regulators have given the green light to ...
AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. The U.S. Food and Drug Administration said late on Friday it granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.
Lung cancer is the leading cause of cancer death in the United States, with an estimated 222,500 new diagnoses and 155,870 deaths in 2017, according to the National Cancer Institute. In 2017, the drug was approved to treat a type of bladder cancer in patients whose disease progressed despite chemotherapy.
The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's , immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed. Imfinzi, chemically known as durvalumab, belongs to a new class of oncology drugs called PD-L1 inhibitors that block a mechanism tumors use to evade detection from the immune system. Lung cancer is the leading cause of cancer death in the United States, with an estimated 222,500 new diagnoses and 155,870 deaths in 2017, according to the National Cancer Institute.
By Kit Rees LONDON (Reuters) - A rally in miners and stocks exposed to South Africa helped Britain's top share index close higher for a second day in a row on Thursday, stabilising after last week's hefty ...
An Irish drugmaker has put a price tag of almost $3,000 on a bottle of two-in-one painkillers that can be bought separately for $36, in another instance of gouging in the US, the world’s largest healthcare ...
By Kit Rees and Helen Reid LONDON (Reuters) - A recovery among commodities stocks helped Britain's top share index outperform European peers on Tuesday, though it came under pressure from a firmer pound ...
By Danilo Masoni and Kit Rees MILAN/LONDON (Reuters) - The UK's top share index fell on Thursday after the Bank of England raised the prospect of higher interest rates, sending the pound higher which weighed ...
"Age is just a number, not a state of mind or a reason for any type of particular behavior." -Cecelia Ahern Alzheimer's disease is the sixth leading cause of death in the U.S., although recent ...
GlaxoSmithKline (GSK.L) sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year. Despite this threat and looming competition from a new Gilead Sciences (GILD.O) HIV drug, Chief Executive Emma Walmsley is more optimistic GSK will deliver on a promise of mid to high single digit earnings growth in the five years to 2020. Walmsley, who took over 10 months ago, is battling to rebuild GSK's drug pipeline by refocusing its research and appointing heavyweight outsiders, such as veteran Roche (ROG.S) scientist Hal Barron.
The drugmaker says its findings advanced the scientific understanding of how to treat lung cancer, but critics say a major overhaul of the clinical trial design sullied the results.
French lender BNP Paribas reported a worse than expected net profit for its fourth quarter of 2017, falling 1.1 percent to 1.43 billion euros ($1.77 billion) and missing market expectations.